BOSTON, Mass. — SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, announced the promotion of Vivi Boura, M.D., Ph.D., to chief medical officer. Dr. Boura is an accomplished oncologist with extensive experience in the clinical development of innovative cancer therapies.
“Vivi’s profound commitment to improving patient outcomes, combined with her deep regulatory expertise, have been invaluable in steering our pipeline’s development and shaping our clinical strategy,” said Radek Spisek, Ph.D., chief executive officer of SOTIO. “As deputy CMO, she has been instrumental in advancing our investigational ADC programs and our broader portfolio of cutting-edge cancer therapies. In this new role, I am confident she will continue to lead our clinical efforts with the focus, rigor, and execution required to bring forward meaningful new options for patients.”
Dr. Boura joined SOTIO in 2021 as a medical director and has since held positions of increasing responsibility within the company’s clinical development team, culminating in her appointment as deputy chief medical officer in February 2025. In that role, she oversaw pre-IND and IND preparations for SOTIO’s antibody-drug conjugate (ADC) pipeline and provided strategic scientific and regulatory leadership across the company’s immunotherapy and ADC programs.
Before joining SOTIO, Dr. Boura served as a medical advisor in AbbVie’s hematology and oncology division. She began her academic and clinical career at the University of Athens, where she was a senior research associate in the 3rd Department of Internal Medicine, Oncology Unit. Over her career, she has contributed to more than 70 Phase 2 and 3 oncology clinical trials, including multinational and investigator-initiated studies. In addition to her clinical and research work, Dr. Boura has taught at the University of Athens and lectured in postgraduate programs on thoracic malignancies. She has authored more than 40 peer-reviewed publications.
